Bausch Health Companies Inc.
CorpDigest
Bausch Health Companies Inc.
Company History
Founded 1994 in Laval, Quebec, Canada
Last reviewed: 2026-06-08 · By Swet Parvadiya
The company that became Bausch Health started not as a pharmaceutical giant but as a small Canadian firm called ICO Corporation, incorporated in 1994. The 2015 collapse began with a congressional hearing where Senator Bernie Sanders displayed a chart showing Valeant's price increases on heart drugs, followed by a Citron Research report questioning the company's accounting and its relationship with the specialty pharmacy Philidor. Pearson was replaced by Joseph Papa, who began the process of shedding assets, cutting debt, and rebuilding relationships with the medical community.
J. Michael Pearson is a Canadian businessman and former CEO of Valeant Pharmaceuticals, who served as the company's chief executive from 2008 to 2016. He played a pivotal role in the company's aggressive expansion, navigating the complex debt financing structures provided by Pershing Square and Oaktree Capital to execute a series of transformational acquisitions. Pearson's background as a McKinsey consultant gave him a unique perspective on the pharmaceutical industry, driving his focus on financial engineering and cost-cutting rather than internal drug discovery. During his tenure, he oversaw the acquisition of over 50 companies, including Coria Laboratories, Medicis, and Salix Pharmaceuticals, which generated tens of billions of dollars in cumulative revenue. Pearson was also known for his controversial pricing strategies, which sparked public outrage and led to a massive SEC investigation and a 96% collapse in the company's stock price in 2015. Despite the controversy, Pearson is widely credited with transforming Valeant from a struggling niche player into a global pharmaceutical powerhouse, although his legacy is permanently tarnished by the regulatory and reputational damage caused by his aggressive tactics.
The corporate lineage of Bausch Health began with the founding of ICO Corporation in Canada, which later merged with Biolyse Pharma to form the foundation of the modern entity.
Biolyse Pharma changed its name to Valeant Pharmaceuticals, marking the beginning of the aggressive acquisition-driven strategy that would define the company for the next two decades.
Valeant acquired Coria Laboratories for $350 million, securing a diversified portfolio of dermatology brands and establishing a foothold in the lucrative topical therapeutics market.
Valeant merged with Biovail in a reverse merger transaction, creating a significantly larger entity with enhanced manufacturing capabilities and a broader international footprint.
Following a Citron Research short-seller report and a subsequent SEC investigation, Valeant's stock price collapsed by 96%, forcing the ousting of CEO J. Michael Pearson and the complete restructuring of the board.
Valeant acquired Salix Pharmaceuticals for $10.3 billion, securing the Xifaxan franchise and establishing a dominant position in the gastroenterology market.
Valeant Pharmaceuticals officially changed its name to Bausch Health Companies Inc., attempting to distance the corporate identity from the toxic legacy of the Valeant era.
Bausch Health acquired the Ortho Dermatologics portfolio from Johnson & Johnson for $800 million, significantly expanding its presence in the acne and psoriasis markets.
Bausch Health acquired Dermira for $1.2 billion, securing the proprietary olumacostat glasaretil asset and expanding its pipeline in the dermatology space.
Bausch Health completed the spin-off of its Bausch + Lomb eye care division, eliminating a $3.8 billion revenue stream but permanently removing the complex intercompany debt guarantees.
Bausch Health reported $8.9 billion in global revenue for FY2024, with operating income reaching $1.8 billion and free cash flow at $2.1 billion, demonstrating strong performance post-spin-off.
Bausch Health acquired Dermira for $1.2 billion to gain control of the proprietary olumacostat glasaretil asset, a first-in-class topical inhibitor of sebaceous lipase for the treatment of acne vulgaris.
Bausch Health acquired the Ortho Dermatologics portfolio from Johnson & Johnson for $800 million, securing a diversified portfolio of topical acne and psoriasis therapies, including Epsolay and Wynzora.
Valeant Pharmaceuticals acquired Salix Pharmaceuticals for $10.3 billion to gain control of the Xifaxan franchise, establishing a dominant position in the gastroenterology market.
Bausch Health's origins as Valeant Pharmaceuticals traced a catastrophic growth-by-acquisition story: CEO Michael Pearson built Valeant from a $1 billion company to a $90 billion peak market cap between 2010-2015 by acquiring drug companies, slashing R&D, and aggressively raising prices on acquired drugs — sometimes 500-1000% overnight. The strategy generated enormous short-term revenue growth but accumulated $30+ billion in debt while creating zero innovative drugs internally. When the strategy unravelled in 2015-2016 amid accounting investigations and scrutiny of its Philidor specialty pharmacy relationship, Valeant's stock collapsed from $263 to $11, destroying $80 billion in market value in one of the fastest corporate implosions in pharmaceutical history.
Valeant renamed itself Bausch Health Companies in June 2018 to distance the company from the toxic 'Valeant' brand destroyed by accounting scandals, predatory drug pricing controversies, and $30+ billion in debt, using the respected Bausch + Lomb eye care name to signal a fresh identity. CEO Joseph Papa, who joined in 2016 after Mike Pearson's ouster, argued that the Valeant name had become an insurmountable liability with customers, physicians, and investors. The rebranding accompanied a strategic shift toward fewer but higher-quality branded pharmaceutical and eye care products, with the Bausch + Lomb division's reputable history in contact lenses and eye health providing legitimate brand equity to borrow against.
Bausch Health completed a partial IPO of Bausch + Lomb in May 2022 at $18 per share, raising $630 million by selling 10% of B+L to public investors, intending to fully separate the eye care business from the pharmaceutical parent's $21+ billion debt burden. The partial separation was meant to unlock value by allowing Bausch + Lomb to trade as a premium eye care company unencumbered by Bausch Health's legacy debt, but the full spinoff stalled because debt covenants required creditor consent that proved difficult to obtain at acceptable terms. Bausch + Lomb traded well below its IPO price by 2023 as investors priced in the complicated corporate structure and debt overhang, and the full separation remained incomplete.
The Philidor pharmacy scandal emerged in October 2015 when Citron Research revealed that Valeant had concealed its relationship with specialty pharmacy Philidor, which submitted fraudulent insurance claims to obtain higher reimbursements for Valeant drugs. Valeant had secretly controlled Philidor through option agreements while publicly denying ownership, using Philidor to manipulate reported revenue by stuffing inventory. The revelation triggered Valeant's 50%+ stock collapse, Congressional investigations into pharmaceutical pricing practices, and SEC probes of the accounting relationship. CEO Pearson went on medical leave during the crisis, returning only to resign in April 2016, and the Philidor channel was shut immediately, reducing Valeant's revenue by $600 million annually overnight.
In September 2010, Mississauga, Ontario-based Biovail Corporation completed a $3.3 billion reverse merger with Valeant Pharmaceuticals International of Aliso Viejo, California, with the combined entity adopting the Valeant name while keeping Biovail's Canadian domicile. The structure was engineered explicitly to harness Canada's lower corporate tax rate, which sat near 26.5% versus the US federal statutory rate of 35%, giving the merged group an effective tax rate of roughly 5% in its early years through a combination of Barbados and Luxembourg subsidiaries. CEO Michael Pearson, hired by Valeant in 2008 from McKinsey, used this tax arbitrage as a deal-making weapon: every drug acquired from a US target instantly produced higher after-tax cash flow under the Canadian holding structure, justifying premium prices that domestic rivals could not match. Pearson combined the inversion with aggressive R&D cuts, slashing research spending below 3% of revenue against an industry norm above 15%, and channeling the savings into more than 100 acquisitions between 2010 and 2015. The model briefly made Valeant the largest Canadian listed company by market capitalisation at C$120 billion in August 2015 before US Treasury anti-inversion rules in 2016 and the Philidor scandal eroded the structural advantage.